What Cagrilintide Is
Cagrilintide is a synthetic long-acting analog of amylin — a hormone your pancreas produces alongside insulin. Amylin's job is to help regulate appetite, slow gastric emptying, and blunt post-meal blood sugar spikes. It's a real part of your metabolic system that most people have never heard of, largely because it's been overshadowed by insulin in the diabetes conversation.
In people with obesity or type 2 diabetes, amylin signaling is often impaired — which is part of why appetite regulation is so difficult even when other hormones are working normally. Cagrilintide is formulated as a once-weekly subcutaneous injection alongside semaglutide. The fixed-dose combination — cagrilintide 2.4mg plus semaglutide 2.4mg — is called CagriSema.
What the Research Shows
The REDEFINE 1 Phase 3 trial is the headline. 3,417 adults with obesity or overweight plus at least one comorbidity were randomized to CagriSema, cagrilintide alone, semaglutide alone, or placebo for 68 weeks. The results, published in the New England Journal of Medicine in 2025, showed CagriSema produced 22.7% average weight loss — compared to 16.1% with semaglutide alone and 11.8% with cagrilintide alone.
More than half of CagriSema participants achieved 20% or more total weight reduction. 88% of participants with prediabetes returned to normoglycemia by the end of the trial. The combination also significantly improved systolic blood pressure, waist circumference, lipid levels, and glycemic control — outperforming both components in monotherapy across every major endpoint.
The side effect profile was consistent with the GLP-1 class — mostly mild to moderate gastrointestinal symptoms, no new safety signals identified.
Why It Matters on a GLP-1 Journey
If you are on semaglutide now, CagriSema represents the most likely next step in the class — not a replacement for what's working, but an addition to it. The amylin pathway acts in the brain's satiety centers through different receptors than GLP-1. That's why combining them produces results neither achieves alone — they are not redundant, they are complementary.
For people who have plateaued on semaglutide, or who are managing well and wondering what the next generation of treatment looks like, this is the answer currently in front of the FDA. This is Novo Nordisk — the same company that makes Ozempic and Wegovy — running proper Phase 3 trials and filing through the standard regulatory process. Your doctor will be talking about this within the year.
"The mean weight reduction observed with cagrilintide–semaglutide is in the highest range of that observed with existing weight-loss interventions." — REDEFINE 1 investigators, New England Journal of Medicine, 2025
I've been on semaglutide, tirzepatide, and now retatrutide. Every time a new compound enters the conversation, I do my homework before my next provider appointment. Cagrilintide is the one I'm watching most closely right now — not because it's exotic, but because it's the logical next step from something I already know works. The REDEFINE 1 numbers are real, the NEJM doesn't publish junk, and Novo Nordisk doesn't file NDAs on weak data. If you're on semaglutide now and wondering what comes next, start learning this name.